[關(guān)鍵詞]
[摘要]
目的 考察多西他賽聯(lián)合順鉑、氟尿嘧啶腹腔灌注治療胃癌晚期患者的臨床效果。方法 選取2011年1月—2015年12月于安徽醫(yī)科大學(xué)附屬第四醫(yī)院診治的晚期胃癌患者100例,采用隨機(jī)數(shù)字法分為試驗組(48例)和對照組(52例),對照組患者給予多西他賽聯(lián)合順鉑、氟尿嘧啶靜脈治療,試驗組患者給予多西他賽聯(lián)合順鉑、氟尿嘧啶腹腔灌注,比較兩組患者的臨床治療有效率、不良反應(yīng)發(fā)生率及2年復(fù)發(fā)率和病死率。結(jié)果 試驗組患者的臨床治療有效率為77.08%,對照組患者的臨床治療有效率46.15%,差異具有統(tǒng)計學(xué)意義(P<0.05)。試驗組患者的不良反應(yīng)發(fā)生率為14.58%,對照組患者的不良反應(yīng)發(fā)生率為34.62%,差異具有統(tǒng)計學(xué)意義(P<0.05);與對照組相比,試驗組患者的復(fù)發(fā)率顯著降低,差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 多西他賽聯(lián)合順鉑、氟尿嘧啶腹腔灌注治療胃癌晚期患者的臨床效果較好,可顯著降低患者的復(fù)發(fā)率,安全性也較好。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of docetaxel combined with cis-platinum, fluorouracil with abdominal cavity perfusion in the treatment of advenced gastric carcinoma.Methods From January 2011 to December 2015 were collected 100 cases advenced gastric carcinoma patients in the fourth affiliated hospital of Anhui medical university, according to randm numbers divided into experimental group (48 cases) and control group (52 cases), the control group was given docetaxel and cis-platinum, fluorouracil through intravenous, the experimental group was given docetaxel combined with cis-platinum, fluorouracilabdominal cavity perfusion, compared with the effect rate of clinical treatment, incidence of adverse reaction and recurrence rate and death rate after two years.Results The effect rate of clinical treatment of experimental group is 77.08%, the effect rate of clinical treatment of control group is 46.15%, the difference was statistically significant (P<0.05). The incidence of adverse reaction of experimental group is 14.58%, the incidence of adverse reaction of control group is 34.62%, the difference was statistically significant (P<0.05). Compared with the control group, the recurrence rate of the experimental group significantly decreased, the difference was statistically significant (P<0.05).Conclusion Docetaxel combined with cis-platinum, fluorouracil with abdominal cavity perfusion in the treatment of advenced gastric carcinoma has good effect, can significantly decreased the recurrence rate, the safety is high.
[中圖分類號]
[基金項目]